Epoxylipids and soluble epoxide hydrolase in heart diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F22%3A00556810" target="_blank" >RIV/67985823:_____/22:00556810 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/22:00081916 RIV/00216208:11130/22:10434794

Výsledek na webu

<a href="https://doi.org/10.1016/j.bcp.2021.114866" target="_blank" >https://doi.org/10.1016/j.bcp.2021.114866</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.bcp.2021.114866" target="_blank" >10.1016/j.bcp.2021.114866</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Epoxylipids and soluble epoxide hydrolase in heart diseases

Popis výsledku v původním jazyce

Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manip-ulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epox-ylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ven-tricular tachycardia, and heart failure.

Název v anglickém jazyce

Epoxylipids and soluble epoxide hydrolase in heart diseases

Popis výsledku anglicky

Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manip-ulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epox-ylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ven-tricular tachycardia, and heart failure.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30105 - Physiology (including cytology)

Projekt

<a href="/cs/project/GA18-03207S" target="_blank" >GA18-03207S: Vliv exprese lidského C-reaktivního proteinu na ischemickou toleranci srdce spontánně hypertenzních potkanů.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biochemical Pharmacology

ISSN

0006-2952

e-ISSN

1873-2968

Svazek periodika

195

Číslo periodika v rámci svazku

Jan

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

114866

Kód UT WoS článku

000777271600005

EID výsledku v databázi Scopus

2-s2.0-85120733144